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The recommended systemic therapy of choice for discoid lupus erythematosus (DLE) is the 4-aminoquinolone
antimalarial hydroxychloroquine. There is limited published information on the likelihood of clinical response
and, in particular, what factors influence outcome. We conducted a multicenter observational and
pharmacogenetic study of 200 patients with DLE treated with hydroxychloroquine. The primary outcome was
clinical response to hydroxychloroquine. We investigated the effects of disease attributes and metabolizing
cytochrome P450 (CYP) polymorphisms on clinical outcome. Although the majority of patients responded to
hydroxychloroquine, a significant proportion (39%) either failed to respond or was intolerant of the drug.
Cigarette smoking and CYP genotype did not have any significant influence on response to hydroxychlor-
oquine. Moreover, multivariate analysis indicated that disseminated disease (odds ratio (OR): 0.21; 95%
confidence interval (CI): 0.08–0.52; Po0.001) and concomitant systemic lupus erythematosus (SLE; OR: 0.06; 95%
CI: 0.01–0.49; P¼ 0.009) were significantly associated with lack of response to hydroxychloroquine. These
findings suggest that baseline lupus severity and SLE are predictors of response to hydroxychloroquine. A
prospective study is now required to further investigate the relationship between disease activity and response
to hydroxychloroquine. This will have the potential to further inform the clinical management of this disfiguring
photosensitive disease.
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INTRODUCTION
Discoid lupus erythematosus (DLE) is the most common form
of cutaneous lupus, (Tebbe and Orfanos, 1997; Kyriakis et al.,
2007) and can cause irreversible scarring and disfigurement.
Hydroxychloroquine is the oral therapy of choice (Jessop
et al., 2009; Walling and Sontheimer, 2009). The factors
influencing clinical response to hydroxychloroquine are
unclear. Small single-site retrospective studies (Rahman
et al., 1998; Jewell and McCauliffe, 2000) have suggested
that cigarette smoking is associated with poor response to
hydroxychloroquine, but this has not been confirmed
prospectively (Lardet et al., 2004) and potential confounding
variables have not been assessed. Nevertheless, this possible
association has come to be a widely accepted ‘‘fact’’ in
dermatology literature and clinics alike (Kuhn et al., 2010).
Patients with systemic lupus erythematosus (SLE) and
rheumatoid arthritis, treated with hydroxychloroquine, de-
monstrate a positive correlation between whole-blood
hydroxychloroquine levels and clinical response (Tett et al.,
1993, 2000; Munster et al., 2002; Costedoat-Chalumeau
et al., 2006). It is plausible that variation in therapeutic
response to hydroxychloroquine might, in part, be due to
inherent differences in hepatic metabolism of hydroxychlor-
oquine between individuals, which therein influence
whole-blood hydroxychloroquine levels. Chloroquine is
metabolized by the cytochrome P450 (CYP) enzymes
CYP2C8, CYP3A4, and CYP2D6 (Kim et al., 2003; Projean
et al., 2003), with CYP2C8 contributing the most. As
hydroxychloroquine and chloroquine differ in structure by
only one hydroxyl group, it is very likely that hydroxychloro-
quine is also metabolized by the same enzymes.
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Few functionally significant polymorphisms of CYP3A4
have been identified and are extremely rare in the United
Kingdom. Although it is not known whether polymorphisms
in CYP2C8 and 2D6 account for part of the differential
response of DLE to hydroxychloroquine, the metabolism of
the antimalarial amodiaquine (structurally related to chlor-
oquine) appears to be impaired in individuals with CYP2C8
polymorphisms (Gil and Gil Bergluand, 2007; Parikh et al.,
2007). If CYP2C8 and/or CYP2D6 polymorphisms are
associated with impaired metabolism of hydroxychloroquine,
individuals possessing these variant alleles might respond
better to hydroxychloroquine than those that are wild type
(via an indirect effect on hydroxychloroquine levels). How-
ever, the importance of such effects on response in
comparison with host or disease attributes (such as smoking
status or disease extent) is unknown.
We conducted a multicenter observational and pharmaco-
genetic cohort study in 200 patients with DLE treated with
hydroxychloroquine. The outcomes of interest were: (i) the
clinical response to hydroxychloroquine and (ii) the effects of
disease attributes, smoking, and metabolizing CYP poly-
morphisms on clinical response.
RESULTS
The median age at diagnosis was 40 years (range 16–81), with
a female to male ratio of 4:1. Median follow-up was for 8
years (range 0.5–37). In all, 92% of patients were seen in
standard dermatology clinics (spanning both district general
and teaching hospitals) and 8% were ‘‘tertiary referrals’’ (i.e.,
referrals sent from one dermatologist to another for further
management). A total of 11 patients (5.5%) had SLE; 8 had
inflammatory arthritis; 5 had nephritis, including 1 requiring
renal transplant; 2 had mouth ulcers; and 1 had pulmonary
fibrosis.
CYP2C8 and 2D6 polymorphisms
Raw allele numbers (n) and allele frequencies (f) were
consistent with those expected amongst Caucasians. For
CYP2D6*1: n¼300, (f) 0.75; *3: n¼ 3, (f) 0.01; *4: n¼ 83, (f)
0.21; and *5: n¼ 14, (f) 0.04. For CYP2C8*1: n¼ 324, (f)
0.81; *3: n¼50, (f) 0.13; and *4: n¼ 26, (f) 0.07.
Response within 6 months
Response to hydroxychloroquine occurred in 120 patients
(60%). A total of 70 patients (35%) were non-responders, and
in 8 patients (4%), therapy was withdrawn early because of
adverse effects (three with gastrointestinal events, three with
rashes, one with malaise, and one with palpitations) before
response could be assessed. In two patients (1%), response to
hydroxychloroquine alone was equivocal because it was
commenced in conjunction with mepacrine from the outset.
Clinical characteristics and outcome to therapy
Table 1 indicates the clinical characteristics of the patients
and the results of univariate logistic regression analysis. All
200 patients satisfied our inclusion criteria for a previous
histological and clinical diagnosis of DLE. At the time of
recruitment, there were two patients who had some clinical
signs of subacute cutaneous lupus in addition to their DLE.
These overlap features had only emerged years after receiving
hydroxychloroquine for DLE and were still not the predomi-
nant feature of their disease. As both patients received
hydroxychloroquine at a time when they only had DLE, a
response to therapy could still be assigned for that period in
time. These two patients, who were both responders to
hydroxychloroquine, were not excluded from the analysis.
The patients who had equivocal response (n¼2) or withdrew
from therapy because of side effects before response being
assignable (n¼8) were excluded from analysis.
Patients with localized disease were significantly more
likely to respond compared with those who had disseminated
disease (odds ratio (OR): 7.29; 95% confidence interval (CI):
3.16–16.79; Po0.0001). There was a significant trend for
increasing number of body sites affected with DLE to be
associated with reduced probability of response (test for
trend; P¼ 1.78106). In addition, those patients without
associated features of SLE were also significantly more likely
to respond in contrast to those with SLE (OR: 19.83; 95% CI:
2.48–159; P¼ 0.005).
During the first 6 months of hydroxychloroquine use, 75
patients (38%) did not smoke, of whom 43 (57%) responded
and 29 (39%) did not. A total 125 patients (63%) were regular
smokers, of whom 77 (62%) responded and 41 (33%) did not.
During the first 6 months of hydroxychloroquine use, there
was no significant difference in the response rate between
non-smokers compared with smokers (OR: 0.78; 95% CI:
0.43–1.45; P¼ 0.27).
Table 2 shows the cohort’s CYP genotypes alongside their
response. There was a nonsignificant trend for CYP2C8 and
2D6 variants to be associated with response to hydroxy-
chloroquine. However, the ORs detected are in the range of
1.20–1.55 (with wide CIs), in contrast to some of the
significant effect sizes demonstrated in Table 1.
Table 3 shows the results of the multivariate logistic
regression analysis. Localized disease remained significantly
associated with response to hydroxychloroquine (OR: 4.80;
95% CI: 1.93–11.97; P¼ 0.001). In contrast, DLE with
concomitant SLE was significantly associated with low odds
of response to hydroxychloroquine (OR: 0.06; 95% CI:
0.01–0.49; P¼0.009). This refers to the lack of response of
DLE itself to therapy and not to the response of the other
manifestations of SLE. Tertiary referrals were also associated
with poor response to hydroxychloroquine (OR: 0.16; 95%
CI: 0.04–0.66; P¼0.011). All tertiary referrals were seen at
one center. After exclusion of this particular tertiary referral
center, there was no significant difference amongst the
remaining seven centers within the response rates
(P¼0.36). After excluding all tertiary referrals from the
analysis, 35% of the remaining 183 patients still either failed
to respond to or withdrew from hydroxychloroquine and the
factors associated with response in the univariate and
multivariate analyses remained the same.
DISCUSSION
This is the largest study of patients with DLE investigated for
response to hydroxychloroquine. Although the majority
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responded to hydroxychloroquine, a significant proportion
(39%) either failed to respond to the drug or developed
toxicity, requiring withdrawal of therapy. This emphasizes the
need to investigate the reasons for poor response to therapy.
Clinical characteristics of the cohort were similar to those
reported by others (Vera-Recabarren et al., 2010). Multi-
variate analysis showed that localized disease (involving
three or less body sites) and absence of concomitant SLE were
significantly associated with response to hydroxychloro-
quine. We found that individuals with disseminated DLE
(including disease in non-photodistributed sites and/or
scarring alopecia), and/or features indicating current or
emerging SLE, were unlikely to respond to hydroxychlor-
oquine. In these patients, close monitoring might be prudent
and other therapies might need to be considered early during
the course of their disease in an attempt to avoid disfiguring
scarring.
A recent single-center cross-sectional study of 114 patients
with cutaneous lupus indicated that treatment-refractory
patients were more likely to have generalized disease
(Moghadam-Kia et al., 2009). Whether generalized disease
was a consequence of poor response to therapy or had an
influence on outcome to therapy is difficult to discern, as the
majority of patients assessed were already receiving estab-
lished medical care when included for analysis. In contrast,
our study has reported the clinical characteristics of patients
before hydroxychloroquine being commenced and shown
that disease extent does influence eventual response.
Table 1. Univariate logistic regression analysis testing association between clinical factors and response
Variable
Non-
responder Responder Test
OR (95% CI)
for response P-value
M 17 23 M versus F 0.73 (0.36–1.50) 0.26
F 53 97
Sites affected
1 20 65
2 20 40
3 4 6 Test for trend 0.538 per site (0.42–0.69) 1.78 106
4 14 5
5 11 4
6 1 0
Localized 44 111 Localized versus disseminated 7.29 (3.16–16.79) o0.0001
Disseminated 26 9
Sites affected include all
photodistributed areas
43 100 Photodistributed only versus
non-photodistributed
3.13 (1.59–6.19) 0.001
Sites affected include
non-photodistributed areas
27 20
No scarring alopecia 32 77 No scarring alopecia versus
scarring alopecia
2.13 (1.17–3.88) 0.014
Scarring alopecia 38 43
Non-smoker 29 43 Non-smoker versus smoker 0.78 (0.43–1.45) 0.27
Smoker 41 77
200 mg od dose 13 32 bd versus od 0.58 (0.28–1.19) 0.09
200 mg bd dose 57 81
200 mg tds dose 0 7 Test for trend 0.26
ANF ve or borderline/ENA/dsDNA ve 34 76 ve versus +ve 1.87 (0.97–3.63) 0.062
ANF +ve and/or ENA +ve/borderline
and/or dsDNA +ve/borderline
26 31
With SLE 10 1 SLE versus no SLE 0.05 (0.01–0.40) 0.005
Without SLE 60 119
Tertiary 14 3 Tertiary versus non-tertiary 0.10 (0.03–0.37) o0.0001
Non-tertiary 56 117
Abbreviations: ANF, anti-nuclear factor; bd, twice daily; CI, confidence interval; dsDNA, double-stranded DNA; ENA, extractable nuclear antigen;
F, female; M, male; od, once daily; OR, odds ratio; SLE, systemic lupus erythematosus; tds, three times daily.
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Our study did not demonstrate a significant association
between CYP genotype and response, although there was a
trend for CYP2C8 variants to be associated with greater odds
of response. These variants have previously been demon-
strated to be associated with slow metabolism of several
drugs (e.g., Parikh et al., 2007; Niemi et al., 2003), although
their precise effect on hydroxychloroquine has not been
examined. If the true effect of CYP polymorphisms on chance
of response approximates to an OR of 1.55 as we have found,
further power calculations indicate that an extra 500 patients
would be required to establish this association (at 1%
significance level and maintaining 80% power).
Previous studies have indicated that B80% of patients
with cutaneous lupus are smokers (Miot et al., 2005; Boeckler
et al., 2009) and our data is consistent with this. It has been
suggested that cigarette smoking might influence the response
of DLE to antimalarials, but studies have been contradictory
(Rahman et al., 1998; Jewell and McCauliffe, 2000; Lardet
et al., 2004). We have demonstrated no significant difference
in response rates between smokers and non-smokers, casting
doubt on the notion that smoking per se inhibits response to
antimalarials in DLE. Unlike other studies (Rahman et al.,
1998; Jewell and McCauliffe, 2000), we controlled for
confounding variables and our cohort is at least four times
larger than others. This finding marks an important reversal of
dermatology dogma.
Although there are limitations in undertaking a retro-
spective assessment of response, we attempted to minimize
the potential for bias with the following measures: a single
investigator recruited and interviewed all patients, reviewed
their case notes according to a predefined protocol, and
importantly used a comprehensive, prespecified adjective list
to designate response. We have since developed a scoring
instrument for measuring DLE activity, which can be used
prospectively to provide more robust studies of disease
response and effect of CYP genotype (Wahie et al., 2010).
In summary, we have identified that at least one in three
patients with DLE fail to respond to the hydroxychloroquine
within 6 months. Both disseminated disease and SLE at
baseline are associated with poor outcome. In contrast, CYP
genotype and smoking have no significant effect on response.
A prospective study is now required to further test
whether baseline disease severity and associated SLE predict
response to hydroxychloroquine therapy. If this is confirmed,
future studies will need to concentrate on the potential
factors influencing disease activity. These might include
effects of disease susceptibility genes and proinflammatory
cytokines.
MATERIALS AND METHODS
In order to be included into the study, patients needed to have:
(i) a clinical diagnosis of DLE with features of scarring, erythematous,
and/or scaly plaques; (ii) a lesional skin biopsy demonstrating a
periadnexal and/or perivascular chronic inflammatory infiltrate and
epidermal ‘‘lichenoid’’ interface change; and (iii) previous treatment
with hydroxychloroquine.
Power calculations indicated that with 200 patients, the study
would have 80% power to detect an OR of between 2 and 2.5
between non-responders and responders with respect to the CYP
Table 2. Univariate logistic regression analysis testing associations between CYP genotype and response
CYP gene Genotype Non-responder Responder Test OR (95% CI) for response P-value
2C8 *1/*1 (WT) 51 76 All mutants versus WT 1.55 (0.82–2.96) 0.18
*1/*3 10 18
*3/*4 1 1
*3/*3 2 7
*1/*4 6 18
2D6 *1/*1 (WT) 40 63 All mutants versus WT 1.20 (0.67–2.18) 0.54
*1/*4 21 42
*1/*3 1 1
*4/*4 4 3
*3/*4 0 1
*1/*5 4 8
*4/*5 0 2
Abbreviations: CI, confidence interval; CYP, cytochrome P450; OR, odds ratio; WT, wild type.
Table 3. Multivariate logistic regression analysis
showing factors associated with response
Variable OR (95% CI) for response P-value
Localized disease 4.80 (1.93–11.97) 0.001
SLE 0.06 (0.01–0.49) 0.009
Tertiary referral 0.16 (0.04–0.66) 0.011
Abbreviations: CI, confidence interval; OR, odds ratio; SLE, systemic
lupus erythematosus.
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genotype frequencies (at 1% significance level). Patients were
recruited from eight centers and interviewed in person by a single
investigator. The study received regulatory approvals from the
Multicentre Research Ethics Committee (MREC) and the Medicines
and Healthcare Products Regulatory Agency (MHRA) and was
conducted according to the Declaration of Helsinki Principles.
Written informed consent was obtained from all patients.
Case notes were reviewed by the same investigator for: age at
diagnosis; body sites affected by DLE at the clinic assessment
immediately before commencing hydroxychloroquine, the ‘‘photo-
distributed’’ sites were the scalp, face, neck, arms, and hands, and
the ‘‘non-photodistributed’’ sites were the torso, legs, and feet;
disease extent (‘‘localized disease’’ was defined as DLE in three or
less body sites and ‘‘disseminated disease’’ as DLE in four or more
body sites); presence or absence of scarring alopecia; features of
concomitant SLE (Hochberg, 1997); drug, alcohol, and smoking
history (Ghaussy et al., 2003); disease duration; starting dose of
hydroxychloroquine; height and weight; side effects; length of
hospital follow-up; presence of antinuclear antibody (positive if
41:40 titer); precipitating antibodies to extractable nuclear antigens
(Ro/SS-A and La/SS-B); and anti double-stranded DNA antibody
(normal range 0–25 U ml1).
An assessment of response to hydroxychloroquine by 6 months of
use was informed by a retrospective case note reviewed by a single
investigator. A predefined list was formulated containing 20
commonly used adjectives and phrases, which were likely to be
used in medical case notes, to formalize retrospective designation of
response. Examples of adjectives or phrases used to denote response
by 6 months included: ‘‘better’’, ‘‘good’’, ‘‘significant improve-
ment’’, ‘‘improved’’, ‘‘melted away’’, ‘‘controlled’’, ‘‘all clear’’,
‘‘virtually clear’’, ‘‘some improvement’’, and ‘‘lesions going/gone.’’
Examples of adjectives or phrases used to indicate non-response by 6
months included: ‘‘no change’’, ‘‘same’’, ‘‘not improving’’, ‘‘worse’’,
‘‘no better’’, ‘‘new lesions arising’’, ‘‘therapy needs changing’’, and
‘‘no significant change’’. All physician notes indicating patient
progress to therapy during the first 6 months were documented to
support the investigator’s final classification of outcome.
Utilizing this approach, patients were classified as responders by
6 months if there had been an improvement in their disease
and no other oral therapies were required to achieve that
improvement. Patients were deemed to be non-responders
by 6 months if their disease did not change or had worsened and/
or other oral therapies had been needed as a consequence. This
definition of response is similar to that used in other retrospective
and prospective studies assessing response to antimalarials in
the context of cigarette smoking (Jewell and McCauliffe, 2000;
Lardet et al., 2004).
All patients donated whole blood (10 ml), and genomic DNA was
isolated (Daly et al., 1996). Samples were genotyped using PCR-
RFLP for CYP2D6*3, *4, and *5 (Daly et al., 1996) and for
CYP2C8*3 and *4 (Bahadur et al., 2002; Niemi et al., 2003).
Statistical analysis
Univariate logistic regression analysis was performed (using STATA,
Timberlake, London) to determine whether the CYP genotypes and
clinical variables were associated with response. For each of the CYP
genes of interest (2C8 and 2D6), response of wild-type (*1/*1)
individuals was compared with heterozygotes and homozygous
mutants combined. Multivariate logistic regression analysis was
undertaken putting all significant variables from the initial univariate
analysis into a model and retaining them if they remained
significantly associated with response (after adjustment for other
factors) using a forward stepwise approach.
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